Cost-effectiveness of clopidogrel vs. ticagrelor in patients of 70 years or older with non-ST-elevation acute coronary syndrome

OBJECTIVE: The POPular AGE trial showed that clopidogrel significantly reduced bleeding risk compared with ticagrelor without any signs of an increase in thrombotic events. The aim of this analysis was to estimate the long-term cost-effectiveness of clopidogrel compared with ticagrelor in these pati...

Descripción completa

Detalles Bibliográficos
Autores principales: van den Broek, Wout W A, van Paassen, Jacqueline G, Gimbel, Marieke E, Deneer, Vera H M, ten Berg, Jurriën M, Vreman, Rick A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9753095/
https://www.ncbi.nlm.nih.gov/pubmed/35723240
http://dx.doi.org/10.1093/ehjcvp/pvac037

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9753095/
https://www.ncbi.nlm.nih.gov/pubmed/35723240
http://dx.doi.org/10.1093/ehjcvp/pvac037

Ejemplares similares